Other News To Note
Wednesday, September 18, 2013
• Compugen Ltd., of Tel Aviv, Israel, said an immune system checkpoint protein, CGEN-15049, showed an ability to regulate an array of different immune cells, making it a potential target for monoclonal antibody immunotherapy in the area of cancer.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.